College Stock: Penny Stock News

The Dean’s List for Monday 4/27/09 only contains penny stocks that may outbreak breakout due to the Swine Flu epidemic. One of The Dean’s top students is an expert in the field of Pharmacy and together we’ve developed a list of 12 potential Swine Flu plays. Our segmentation strategy was to focus on respiratory-related biotech stocks with existing momentum. It’s a pure gamble which of these stocks will catch ‘Swine Mania’ but the upside potential can be astronomical.

NVAX uses a virus-like particle platform technology for infectious diseases including multiple strains of influenza, H5N1, shingles and Respiratory Syncytial Virus.

ADLS has a leading candidate called Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pnemonia. It’s also completed Phase III clinical trials for the treatment of respiratory tract infections.

BCRX engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.

GNVC is developing a product called TherAtoh, a potential vaccination for respiratory syncytial virus, HSV-2, malaria, HIV and foot-and-mouth disease.

DVAX products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases.

HEB develops multiple products for the treatment of West Nile Virus, SARS, genital wards and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.

HGSI development pipeline includes drugs to treat inhalation anthrax, hepatitis C and lupus.

IMM programs include hepatitis C virus, fungal diseases, and multi-drug resistant strains of bacterial infections.

INHX develops anti-infective products to treat serious infections including shingles, chicken pox and herpes.

INSM engages in the development of recombinant protein drugs. Their IPLEX product is a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions.

SVA engages in the sale of vaccines that protect against human infectious diseases primarily in China. Their Anflu drug provides a split virus influenza vaccine.

VICL develops products based on its DNA delivery technologies for the prevention and treatment of diseases including H5N1 pandemic influenza virus and cytomegalovirus.

MCET has a $1.4M market cap and is trading at $0.01. According to the company’s website, their MCT-465 drug candidate is a Toll-like Receptor (TLR) agonist, and is indicated as prospective therapy for treatment of virus infections including influenza A H1N1 and the “avian flu” virus.

HALO has a treatment called Gammagard. It’s a sterilized solution made from human plasma that contains the antibodies to help your body protect itself against infection from various diseases. A $30 billion company, Baxter International (BAX), has partnered with HALO for the distribution of Gammagard and must pay royalties for its use.

AVII is developing drugs for the treatment of rare viruses and conducts research in collaboration with the U.S. Army. The majority of this collaboration has been supported by a research contract from the Department of Defense’s Transformational Medical Technologies Iniative with the goal of developing new antiviral drugs.

XOMA is currently engaged in more than 16 active development projects across multiple therapeutic areas including autoimmune and infectious disease. The company has ongoing contracts with the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) to develop monoclonal antibody products.

LWLLE is engaged in the development, manufacture, sale and distribution of disinfectant health care products including hand disinfectants, surface disinfectants, equipment disinfectants, machine disinfectants and animal disinfectants.

CBMX has also developed a semiconductor-based DNA chip, the CombiMatrix Influenza A Research Microarray, that can detect and accurately type flu strains with hemagglutinin subtypes 1 through 15 and neuraminidase subtypes 1 through 9 using a protocol that requires less than four hours start to finish. In addition to providing very high resolution information on genotype of any given flu strain, it can also provide information on novel strains of flu produced by rapid mutation or recombination between multiple strains of flu.

CERS has developed an INTERCEPT system that based on its proprietary Helinx technology for controlling biological replication.  The INTERCEPT system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.

CRXL focuses on the development, production and marketing of vaccines and antibodies against infectious disease worldwide. Through its portfolio of core marketed vaccines, the company has established markets in hepatitis B, respiratory and travel vaccines.

GNBT technology focuses on modulating immune responses mediated by T helper (Th) cells, a class of lymphocytes that plays a multifaceted role in the immune system, both enhancing and suppressing immune responses. The cells are essential both for obtaining a robust and long lasting response against infectious agents or cancer cells and for down regulating immune responses when the immune system becomes inappropriately stimulated, e.g. in autoimmune disease and allergy.

NNVC is developing a nanoviricided branded as FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

PPHM is developing a portfolio of clinical and preclinical stage monoclonal antibody-based targeted therapeutics, including bavituximab that is in a multi center Phase II clinical trial for the treatment of solid tumors and HCV infection. The company has a third Phase I clinical study to evaluate the safety, pharmacokinetics and anti-viral activity of bavituximab over a longer dosing period in patients co-infected with HCV and the human immunodeficiency virus.

QDEL offers products for infectious diseases, such as Influenza, Group A Strep, and Respiratory Syncitial Virus; and for reproductive and women’s health, including pregnancy, Chlamydia, Bacterial Vaginosis, and Bone Health. It also offers Immunoassay fecal occult blood test used to detect the presence of blood in stool specimens; and Helicobacter pylori test, a serological test to measure antibodies circulating in the blood caused by the immune response to the H. pylori bacterium.

SIGA engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. It focuses on products for use in defense against biological warfare agents, such as smallpox and arenaviruses/hemorrhagic fevers.

GMED is a pink sheet company that uses hereditary information from DNA to improve patient outcomes. Targeted diseases include influenza, SARS, HIV, West Nile Virus and Hepatitis A, B and C.

NVLX sells nutraceutical products worldwide. The company’s Citroxin product is being tested on chicken embryos for bird flu in Thailand, as well as to eradicate the MRSA strain of staph in vitro. They also distribute  the ‘Immune Boost Bar’ designed to enhance overall immune function and help increase resistance to common viruses.

PURE develops silver dihydrogen citrate-based antimicrobials and boric acid-based pesticides that are non-toxic solutions to numerous health challenges. PURE is also developing an EPA registered hard surface disinfectant known as Axen30. It disinfects twenty times faster than other disinfectants and provides a broad spectrum of protection as a disinfectant, fungicide and viricide.

I doubt any of these stocks will actually prevent or cure Swine Flu, but history proves that epidemic plays in the stock market can breakout to absurd prices.

References:
Yahoo covers Swine Flu Stocks